More recent studies have shown that TTI-101 can be given orally and without toxicity (249) and this STAT3 inhibitor is currently being trialled as a monotherapy for solid tumors including HNSCC and GC (Table 1). The gene discussed is STAT3; the disease is head and neck squamous cell carcinoma.